949575-24-0Relevant academic research and scientific papers
PROCESS FOR PRODUCTION OF HETERODIMERS OF GLUTAMIC ACID
-
Page/Page column 17-18, (2010/12/31)
A manufacturing process for the preparation of radiolabeled compounds of formula (I) includes reacting compounds of formula (II) with a source of readionuclide of a halogen in the presence of an oxidant under acidic condition, wherein: *I is 123I, 124I, 125I or 131I; R is lower alkyl, optionally substituted with one or more fluorine atoms; Q is C(O), O, NR', S, S(O)2, C(O)2, (CH2)P; Y is C(O), O, NR', S, S(O)2, C(O)2, (CH2)P; R is H, C(O), S(O)2, C(O)2; Z is H, C1-C4 alkyl, benzyl, substituted benzyl or trialkylsilyl; m is O, 1, 2, 3, 4 or 5; n is O, 1, 2, 3, 4, 5 or 6; and p is O, 1, 2, 3, 4, 5 or 6.
A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer
Maresca,Hillier,Femia,Keith,Barone,Joyal,Zimmerman,Kozikowski,Barrett,Eckelman,Babich
experimental part, p. 347 - 357 (2009/10/17)
Prostate specific membrane antigen (PSMA) is a validated molecular marker for prostate cancer. A series of glutamate-urea (Glu-urea-X) heterodimeric inhibitors of PSMA were designed and synthesized where X = ε-N-(o-I, m-I, p-I, p-Br, o-Cl, m-Cl, p-Cl, p-F
